Litcius/Paper detail

Evaluating SARS-CoV-2 Vaccines After Emergency Use Authorization or Licensing of Initial Candidate Vaccines

Steven Joffe

2020JAMA23 citationsDOI

Abstract

Emergency Use Authorizations During the COVID-19 Pandemic—Lessons From Hydroxychloroquine for Upcoming Vaccine Approval

Topics & Concepts

MedicineCoronavirus disease 2019 (COVID-19)PandemicSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Hydroxychloroquine2019-20 coronavirus outbreakAuthorizationVirologyMedical emergencyOutbreakComputer securityInfectious disease (medical specialty)Computer scienceDiseasePathologyPharmacovigilance and Adverse Drug ReactionsVaccine Coverage and HesitancySARS-CoV-2 and COVID-19 Research
Evaluating SARS-CoV-2 Vaccines After Emergency Use Authorization or Licensing of Initial Candidate Vaccines | Litcius